|
|
| | 2,3-dinor-11β-Prostaglandin F2α-d9 Basic information |
| | 2,3-dinor-11β-Prostaglandin F2α-d9 Chemical Properties |
| solubility | DMF: 100 mg/ml
DMSO: 100 mg/ml
Ethanol: 100 mg/mlPBS (pH 7.2): 10 mg/ml |
| | 2,3-dinor-11β-Prostaglandin F2α-d9 Usage And Synthesis |
| Description | 2,3-dinor-11β-PGF2α-d9 is intended for use as an internal standard for the quantification of 2,3-dinor-11β-PGF2α (Item No. 16530) by GC- or LC-MS. 2,3-dinor-11β-PGF2α is a metabolite of PGD2 (Item No. 12010).1,2 Urinary excretion of 2,3-dinor-11β-PGF2α is increased in patients with mast cell activation disease (MCAD) and has been used as a marker of increased PGD2 levels.3 2,3-dinor-11β-PGF2α levels are also increased in the urine of patients with asthma and are positively correlated with impaired lung function.4WARNING This product is not for human or veterinary use. | | References | [1] T E LISTON L J R. Metabolic fate of radiolabeled prostaglandin D2 in a normal human male volunteer.[J]. The Journal of Biological Chemistry, 1985, 260 24: 13172-13180.
[2] WEN-LIANG SONG. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans.[J]. The Journal of Biological Chemistry, 2008: 1179-1188. DOI: 10.1074/jbc.m706839200
[3] MD M C, PHD Joseph B M. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management[J]. Journal of Allergy and Clinical Immunology-In Practice, 2019, 7 4: Pages 1097-1106. DOI: 10.1016/j.jaip.2019.02.002
[4] JOHAN KOLMERT. Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study.[J]. American journal of respiratory and critical care medicine, 2021: 37-53. DOI: 10.1164/rccm.201909-1869oc |
| | 2,3-dinor-11β-Prostaglandin F2α-d9 Preparation Products And Raw materials |
|